• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[若人工泪液不足:炎症过程在干眼病中的重要性。干眼病抗炎治疗的实际问题]

[If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease].

作者信息

Pleyer Uwe, Geerling Gerd, Schrader Stefan, Jacobi Christina, Kimmich Friedemann, Messmer Elisabeth

机构信息

Universitäts-Augenklinik, Charité - Campus Virchow-Klinik, Berlin.

Augenklinik, Universitätsklinikum Düsseldorf.

出版信息

Klin Monbl Augenheilkd. 2020 May;237(5):655-668. doi: 10.1055/a-1115-4756. Epub 2020 May 20.

DOI:10.1055/a-1115-4756
PMID:32434249
Abstract

Dry eye disease (DED) is a heterogenous disease of the ocular surface. Multiple pathogenetic factors are responsible for the disease process, but DED is generally linked to an increase in the osmolarity of the tear film and to inflammation of the ocular surface. The significance of inflammatory processes in DED is highlighted in the most recent definition of dry eye in the Dry Eye Workshop (DEWS). It is therefore critically important for the management of dry eye disease to understand the pathomechanisms and therapeutic options for the treatment of inflammatory processes. This review summarizes our current knowledge on Inflammation associated with DED and provides practical recommendations for the diagnosis and monitoring of the disease, as well as the use of currently available therapeutic options to counteract inflammation in DED.

摘要

干眼病(DED)是一种眼表的异质性疾病。多种致病因素参与了该疾病的进程,但干眼病通常与泪膜渗透压升高以及眼表炎症有关。眼表炎症在干眼病中的重要性在干眼研讨会(DEWS)对干眼的最新定义中得到了强调。因此,了解炎症的发病机制和治疗方案对于干眼病的管理至关重要。本综述总结了我们目前对与干眼病相关炎症的认识,并为该疾病的诊断和监测以及使用现有治疗方案对抗干眼病中的炎症提供了实用建议。

相似文献

1
[If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease].[若人工泪液不足:炎症过程在干眼病中的重要性。干眼病抗炎治疗的实际问题]
Klin Monbl Augenheilkd. 2020 May;237(5):655-668. doi: 10.1055/a-1115-4756. Epub 2020 May 20.
2
Rationale for 24-hour management of dry eye disease: A review.干眼症 24 小时管理的理由:综述。
Cont Lens Anterior Eye. 2019 Apr;42(2):147-154. doi: 10.1016/j.clae.2018.11.008. Epub 2018 Nov 27.
3
TFOS DEWS II Tear Film Report.TFOS DEWS II 泪膜报告。
Ocul Surf. 2017 Jul;15(3):366-403. doi: 10.1016/j.jtos.2017.03.006. Epub 2017 Jul 20.
4
Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.干眼症治疗:泪液替代物的作用、未来发展及更新分类
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642-8652. doi: 10.26355/eurrev_202009_22801.
5
TFOS DEWS II Diagnostic Methodology report.TFOS DEWS II 诊断方法学报告。
Ocul Surf. 2017 Jul;15(3):539-574. doi: 10.1016/j.jtos.2017.05.001. Epub 2017 Jul 20.
6
Rethinking dry eye disease: a perspective on clinical implications.重新审视干眼病:对临床意义的一种观点
Ocul Surf. 2014 Apr;12(2 Suppl):S1-31. doi: 10.1016/j.jtos.2014.02.002. Epub 2014 Feb 13.
7
Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases.泪液渗透压与其他干眼病诊断测试的性能比较。
Curr Eye Res. 2010 Jul;35(7):553-64. doi: 10.3109/02713683.2010.484557.
8
Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial.开发基于证据的人工泪液补充剂治疗干眼的指南:一项为期六个月的多中心、双盲随机对照试验。
Ocul Surf. 2021 Apr;20:62-69. doi: 10.1016/j.jtos.2020.12.006. Epub 2021 Jan 2.
9
The epidemiology of dry eye disease in the UK: The Aston dry eye study.英国干眼疾病的流行病学:阿斯顿干眼研究。
Cont Lens Anterior Eye. 2023 Jun;46(3):101837. doi: 10.1016/j.clae.2023.101837. Epub 2023 Mar 30.
10
The pathophysiology, diagnosis, and treatment of dry eye disease.干眼症的病理生理学、诊断及治疗
Dtsch Arztebl Int. 2015 Jan 30;112(5):71-81; quiz 82. doi: 10.3238/arztebl.2015.0071.

引用本文的文献

1
Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study.0.1%环孢素A对0.05%环孢素A反应欠佳的干眼症患者的临床疗效:一项转换、前瞻性、开放标签、多中心研究。
BMC Ophthalmol. 2025 Jan 22;25(1):37. doi: 10.1186/s12886-025-03862-x.
2
Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.关于环孢素 A 0.1%阳离子乳剂用于德国干眼症长期治疗的真实世界观察和结局:PERSPECTIVE 研究的国家级亚组分析。
Graefes Arch Clin Exp Ophthalmol. 2024 Oct;262(10):3261-3271. doi: 10.1007/s00417-024-06414-z. Epub 2024 May 9.
3
The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Dry Eye Disease Patients.干眼症患者眼睛中导致泪液高渗诱导病理性改变的分子机制。
Cells. 2023 Dec 1;12(23):2755. doi: 10.3390/cells12232755.
4
Management of inflammation in dry eye disease: Recommendations from a European panel of experts.干眼疾病炎症管理:欧洲专家小组的建议。
Eur J Ophthalmol. 2023 May;33(3):1294-1307. doi: 10.1177/11206721221141481. Epub 2022 Dec 5.
5
Inflammation and dry eye disease-where are we?炎症与干眼症——我们目前的进展如何?
Int J Ophthalmol. 2022 May 18;15(5):820-827. doi: 10.18240/ijo.2022.05.20. eCollection 2022.
6
Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.0.1%环孢素A阳离子乳液在重度角膜炎和干眼症治疗中的真实世界有效性、耐受性及安全性
Ophthalmol Ther. 2022 Jun;11(3):1101-1117. doi: 10.1007/s40123-022-00487-x. Epub 2022 Mar 17.
7
A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic.干眼疾病的当前认识与分类的叙述性综述以及关于 COVID-19 大流行期间干眼影响的新见解
Ophthalmol Ther. 2021 Sep;10(3):495-507. doi: 10.1007/s40123-021-00373-y. Epub 2021 Jul 17.